⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837 | 0.65 | — | — | |
| SCHEMBL449578 | 0.65 | — | — | |
| SCHEMBL4216 | 0.65 | — | — | |
| SCHEMBL23702135 | 0.65 | — | — | |
| SCHEMBL29419137 | 0.64 | — | — | |
| SCHEMBL114038 | 0.64 | — | — | |
| SCHEMBL6599224 | 0.63 | ALDH1A1 (0.48) | — | |
| SCHEMBL16097277 | 0.63 | PARP1 (0.43) | — | |
| Benzotriazole SCHEMBL8956 | 0.62 | — | — | |
| SCHEMBL21466101 | 0.62 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | claimed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | claimed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2023150525-A1 | COMPETITIVE AND NONCOMPETITIVE PIPERIDINE SULFONYL INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | claimed |
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | claimed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | claimed |
| CN-113521079-A | Use of IRAK4 inhibitors for the treatment of ALI/ARDS | 上海领泰生物医药科技有限公司 | 2021-10-22 | — | — | CN | claimed |
| EP-3852752-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-07-28 | — | — | EP | claimed |
| EP-3630752-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | claimed |
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | claimed |
| WO-2012047580-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | WO | claimed |
| WO-2012037226-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| WO-2011033094-A1 | SCHEDULE OF ADMINISTRATION OF BENZAZOLE DERIVATIVES IN THE TREATMENT OF LEUKEMIAS | 4SC AG (DE) | 2011-03-24 | — | — | WO | claimed |
| EP-1996583-A1 | THIAZOLES AS NF-KB INHIBITORS (PROTEASOME INHIBITORS) | 4SC AG (DE) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104558-A1 | THIAZOLES AS NF-KB INHIBITORS (PROTEASOME INHIBITORS) | 4SC AG (DE) | 2007-09-20 | — | — | WO | claimed |
| US-20070219190-A1 | Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2007-09-20 | — | — | US | claimed |
| EP-1834954-A1 | Thiazoles as NF-kB Inhibitors (proteasome inhibitors) | 4SC AG (DE) | 2007-09-19 | — | — | EP | claimed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | claimed |
| US-5424313-A | Bibyclic heteroacrylpiperazine derivatives having psychotropic activity, and pharmaceutical compositions containing these derivatives | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1995-06-13 | — | — | US | claimed |